LACTOLOGY FOUNDATION

This web-page monograph describes ATC class A03CA05 as synthetic anticholinergic glycopyrronium in fixed-dose combination with psycholeptics used for functional gastrointestinal disorders. Below is an English, toxicological–lactological oriented monograph structured as web-page content.medpedia.framar+2

ATC A03CA05 – Glycopyrronium and Psycholeptics

ATC code A03CA05 comprises medicines containing glycopyrronium (glycopyrrolate, typically as glycopyrronium bromide) combined with one or more psycholeptics. These combinations belong to the group of synthetic anticholinergic antispasmodics in combination with psycholeptics and are classified under “Drugs for functional gastrointestinal disorders”. Their primary role is to reduce gastrointestinal motility and secretions and to provide anxiolytic or sedative effects in patients with functional gastrointestinal complaints, peptic ulcer disease, or related conditions.atcddd.fhi+6

Pharmacological class and mechanism

Glycopyrronium is a synthetic quaternary ammonium antimuscarinic (anticholinergic) agent that competitively blocks peripheral muscarinic receptors, thereby inhibiting cholinergic transmission in smooth muscle, exocrine glands and the heart. As a quaternary amine it penetrates poorly into the central nervous system, resulting mainly in peripheral actions and minimal central anticholinergic effects.drugbank+4

Psycholeptics are centrally acting agents with sedative, anxiolytic, antipsychotic or hypnotic properties, included here to attenuate anxiety and psychovegetative components of functional gastrointestinal disorders. In A03CA05 combinations, glycopyrronium decreases salivary, gastric and intestinal secretions and reduces smooth muscle tone and spasm, while the psycholeptic component helps relieve tension, anxiety, or agitation that may exacerbate gastrointestinal symptoms.sciencedirect+3

Indications and therapeutic use

Medicinal products in A03CA05 are indicated for functional gastrointestinal disorders where combined antispasmodic and psycholeptic effects are desirable, such as irritable bowel syndrome, peptic ulcer disease and other conditions with painful gastrointestinal spasm and excess secretions. Glycopyrronium reduces salivation, gastric and intestinal secretions and motility, and can be used adjunctively in the treatment of peptic ulcer disease together with other anti-ulcer medicines. Depending on the psycholeptic(s) used, the combination may also be used to reduce anxiety-related gastrointestinal symptoms or to improve tolerance of chronic functional gastrointestinal complaints.wikipedia+4

These preparations are prescription-only medicines and should be used according to local product information and specialist guidance.gsrs.ncats.nih+2

Dosage and administration

The specific dosage regimens of A03CA05 products vary between formulations and national products and must follow the approved summary of product characteristics for each medicinal product. Glycopyrronium in other indications is given orally, intravenously, intramuscularly, subcutaneously, inhaled or topically, with dose individualisation based on indication, age and route. For chronic oral therapy, glycopyrronium is often administered on an empty stomach at least one hour before or two hours after meals to optimise absorption.pch.health+4

For A03CA05 combinations, dosing must take into account both the anticholinergic and psycholeptic components, with titration to the lowest effective dose to minimise adverse effects, especially in elderly patients and those with comorbidities. Before use, patients should consult a physician, who will determine dosage, treatment duration and monitoring requirements.medpedia.framar+2

Contraindications and precautions

A03CA05 medicines are contraindicated in patients with known hypersensitivity to glycopyrronium, the psycholeptic component, or any excipient in the product. General anticholinergic contraindications apply, including untreated narrow-angle glaucoma, urinary retention, severe prostatic hypertrophy, paralytic ileus, severe ulcerative colitis, toxic megacolon and myasthenia gravis.ncbi.nlm.nih+3

Caution is required in patients with cardiovascular disease (tachyarrhythmias, ischemic heart disease, heart failure), autonomic neuropathy, gastro‑oesophageal reflux, or those at risk of reduced gastrointestinal motility. Psycholeptics add further cautions such as central nervous system depression, risk of falls, and potential interactions with other sedative or psychotropic agents.atcddd.fhi+3

Special care is needed in elderly patients due to increased susceptibility to anticholinergic effects (confusion, constipation, urinary retention) and to psycholeptic-related sedation and cognitive impairment. In all cases, risk–benefit evaluation and close clinical monitoring are recommended.pch.health+2

Adverse effects and toxicity profile

Anticholinergic adverse effects of glycopyrronium are common and dose‑dependent. Frequently reported reactions include dry mouth, reduced salivary and respiratory secretions, constipation or diarrhea, nausea, vomiting, urinary retention, tachycardia, headache and visual disturbances. Other anticholinergic effects include inhibition of sweating, flushing, nasal congestion and potential worsening of gastro‑oesophageal reflux.wikipedia+3

The psycholeptic component may contribute drowsiness, dizziness, sedation, impaired concentration, confusion and, depending on the specific agent, extrapyramidal symptoms or mood changes. In paediatric monographs, common adverse effects of glycopyrronium include drowsiness, dizziness, headache, insomnia, tachycardia, dry mouth, urinary retention, impotence and constipation, with infrequent agitation, aggression, paradoxical hyperexcitability and rare angle‑closure glaucoma.sciencedirect+2

Serious toxicity may manifest as pronounced tachycardia, arrhythmias, severe urinary retention, paralytic ileus, hyperthermia (due to abolished sweating), and central or peripheral anticholinergic syndrome. Management of overdose focuses on supportive care, monitoring of cardiovascular and respiratory function, and use of a cholinesterase inhibitor (e.g. physostigmine) in selected cases of severe anticholinergic toxicity, under expert supervision.ncbi.nlm.nih+1

Drug interactions

A03CA05 combinations can interact with various medicinal products. Concomitant use with other anticholinergics (e.g. tricyclic antidepressants, certain antihistamines, antiparkinsonian drugs) may potentiate anticholinergic effects and increase risk of urinary retention, constipation and cognitive impairment. Co‑administration with other psycholeptics, hypnotics, opioids or alcohol can lead to additive CNS depression, psychomotor impairment and increased fall risk.atcddd.fhi+2

Agents that affect gastric motility or pH may alter the absorption of co‑administered oral drugs, particularly those with a narrow therapeutic window, due to glycopyrronium‑induced changes in gastric emptying and secretions. Clinicians should review the patient’s medication profile carefully and adjust therapy or monitoring when combining A03CA05 products with interacting agents.pch.health+2

Use in pregnancy

Available information suggests that glycopyrronium is classified as pregnancy category B in some references, indicating that animal studies have not demonstrated fetal risk, but controlled human data are limited. Due to its peripheral anticholinergic effects, potential impacts on maternal heart rate, gastrointestinal motility and urinary function must be considered, and therapy during pregnancy should be reserved for clear indications after individual risk–benefit assessment.sciencedirect+1

Psycholeptics may carry specific pregnancy and teratogenicity warnings depending on the individual molecule, and their use in combination products should follow national guidelines and obstetric consultation. Overall, A03CA05 combinations should be used during pregnancy only if the expected clinical benefit outweighs potential risks for the fetus and mother.atcddd.fhi+2

Use during lactation (lactological safety)

Data on glycopyrronium excretion into human breast milk and its safety profile in breastfeeding are limited and considered “safety unknown” in some pharmacological overviews. As a quaternary ammonium compound with poor oral bioavailability and limited systemic distribution from the gastrointestinal tract, the amount reaching the breastfed infant after maternal exposure is expected to be low, but clinically relevant effects cannot be excluded.wikipedia+1

Potential lactological concerns include anticholinergic effects in the infant (reduced gastrointestinal motility, urinary retention, dry mouth, potential feeding difficulties) if clinically significant exposure occurs. Moreover, anticholinergic agents can theoretically reduce milk production by inhibiting parasympathetic stimulation of mammary glands, although robust data for glycopyrronium are lacking.ncbi.nlm.nih+2

Psycholeptics may pass into breast milk and cause sedation, hypotonia, feeding difficulties or developmental effects in the infant depending on the specific compound and dose. For A03CA05 combinations, breastfeeding decisions require case‑by‑case evaluation, balancing maternal benefit against potential infant risk, with preference for alternative therapies with better established lactational safety when feasible. If such therapy is deemed necessary during lactation, close monitoring of the breastfed infant for signs of anticholinergic or sedative effects is advisable.pch.health+2

Special populations and clinical monitoring

In paediatric patients, glycopyrronium is used in other indications (e.g. chronic drooling) with carefully titrated dosing and close monitoring of heart rate, anticholinergic effects, bowel function and drooling response. For A03CA05 combinations, use in children is restricted and should follow product‑specific age indications and specialist oversight due to the double pharmacological burden of anticholinergic and psycholeptic agents.sciencedirect+1

In elderly patients, dosage reductions and vigilant monitoring are essential to minimise cognitive impairment, confusion, urinary retention, constipation and falls. Routine monitoring should include assessment of heart rate, bowel sounds and movements, urinary function, mental status and overall tolerability, particularly at treatment initiation and during dose adjustments.ncbi.nlm.nih+2

Regulatory and ATC classification notes

The WHO ATC classification lists A03CA as “Synthetic anticholinergic agents in combination with psycholeptics”, with A03CA05 specifically designated as “glycopyrronium bromide and psycholeptics”. Some veterinary ATC-like classifications similarly reference “glycopyrronium and psycholeptics” with code QA03CA05. These codes support consistent pharmacological grouping of such combinations across national formularies and electronic prescribing systems.atcddd.fhi+2

Preparations containing glycopyrronium in other combinations (e.g. with neostigmine) are classified in different ATC groups and should not be confused with A03CA05 products. Local product information and ATC indexing should be consulted to correctly identify specific formulations and their classification.atcddd.fhi+1